Development and internal validation of a prediction model for patients with hematologic diseases of fall risk: a cohort study
CONCLUSION: Our equation has good sensitivity and specificity in predicting the fall risk of patients with hematologic diseases, and has certain positive significance for clinical assessment of their fall risk.TRIAL REGISTRATION NUMBER: ChiCTR2200063940.PMID:38465408 | DOI:10.1080/17474086.2024.2329596 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - March 11, 2024 Category: Hematology Authors: Huang Xinrui Xu Min Cao Min Xu Chenyi Source Type: research

Development and internal validation of a prediction model for patients with hematologic diseases of fall risk: a cohort study
CONCLUSION: Our equation has good sensitivity and specificity in predicting the fall risk of patients with hematologic diseases, and has certain positive significance for clinical assessment of their fall risk.TRIAL REGISTRATION NUMBER: ChiCTR2200063940.PMID:38465408 | DOI:10.1080/17474086.2024.2329596 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - March 11, 2024 Category: Hematology Authors: Huang Xinrui Xu Min Cao Min Xu Chenyi Source Type: research

Pomalidomide combined with dexamethasone for the treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis
CONCLUSIONS: Pomalidomide combined treatment regimens have shown good clinical efficacy, especially in pomalidomide + dexamethasone combined with other drugs. In terms of safety, it's important to pay attention to the likelihood of hematological adverse events when used clinically.PMID:38421372 | DOI:10.1080/17474086.2024.2326219 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - February 29, 2024 Category: Hematology Authors: Ying Luo Chen Li Yuanchen Niu Shuanzhi Wu Jingyuan Tian Zhiqin Hu Jin He Zhixin Zhang Haiyan Liu Yongmei Li Tenghua Wang Yi Fang Source Type: research

Addressing thrombosis concerns in immune thrombocytopenia: the role of fostamatinib in immune thrombocytopenia management
Expert Rev Hematol. 2024 Jan-Mar;17(1-3):55-66. doi: 10.1080/17474086.2024.2318345. Epub 2024 Feb 19.ABSTRACTINTRODUCTION: Immune thrombocytopenia (ITP), a disease that commonly presents with an increased risk of bleeding, can also paradoxically produce an increased risk of thromboembolic events. The risk of thromboembolism can be associated with patient-related factors (e.g. co-morbidities, age and history of thrombosis), disease-related factors (e.g. a greater proportion of younger, more reactive platelets, and the presence of microparticles and pro-inflammatory cytokines) and treatment-related factors (e.g. splenectomy,...
Source: Expert Review of Hematology - February 19, 2024 Category: Hematology Authors: Drew Provan Jecko Thachil Mar ía Teresa Álvarez Román Source Type: research